Kiora Pharmaceuticals (NASDAQ:KPRX) Issues Earnings Results

Kiora Pharmaceuticals (NASDAQ:KPRX) announced its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.10, FiscalAI reports. The firm had revenue of $1.00 million during the quarter.

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ KPRX traded down $0.03 during trading on Friday, hitting $1.30. 49,888 shares of the company were exchanged, compared to its average volume of 165,686. The company has a fifty day moving average price of $2.31 and a 200-day moving average price of $2.38. The firm has a market capitalization of $5.75 million, a PE ratio of -0.50 and a beta of -0.13. Kiora Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $2.91.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a research report on Monday, October 12th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Kiora Pharmaceuticals currently has a consensus rating of “Sell”.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.